Is Dostarlimab the answer?
In what appears to be a miracle and a historic event, every single rectal cancer patient who received an experimental treatment of Dostarlimab saw their disease vanish.
According to the New York Times, 18 patients in a limited clinical trial conducted by Memorial Sloan Kettering Cancer Center, used a drug called Dostarlimab for six months and saw their malignant tumours decrease at the end.
As the investigation progressed, these patients expected to have to undergo further procedures. They were startled, however, to hear that no further therapy was required.
According to the experts,
“Physical examination, positron emission tomography or PET scans, MRI scans, and endoscopy, were all ineffective in detecting the cancer”.
This suggests that Dostarlimab could be a ‘possible’ cancer treatment for malignant tumors.
To read more about the clinical research, click the link.